Skip to main content

Trump announces temporary pause on new Canada tariffs

Canadian Prime Minister Mark Carney greets U.S. President Donald Trump at the official welcome ceremony during the G7 Leaders’ Summit on June 16, 2025 in Kananaskis, Alberta. (Photo by Chip Somodevilla/Getty Images)

(NEW YORK) — President Donald Trump said he is pausing for three days the new 50% tariffs on Canadian goods set to go into effect early Wednesday, citing a deal between the U.S. and Canada.

“I have paused the 50% Tariffs against Canada, that were scheduled to kick in tomorrow morning for a three day period, based on the fact that Canada and the U.S.A., subject to the finalization of documents, have a DEAL,” Trump said in a social media post.

The new tariffs, targeting dozens of products from hockey sticks to wine, were set to go into effect at 12:01 a.m. ET on Wednesday.

The U.S. Trade Representative’s official account on X responded to Trump’s announcement, providing a bit of insight into what a final deal might entail.

“The deal will include comprehensive market access for all American goods, economic security commitments, digital trade alignment, and many important provisions that will continue to protect our market and American workers, along with our Canadian partners,” the USTR posted.

While the president did not offer specifics about the deal, he did suggest that it might include a renewed effort to build the Keystone Pipeline, despite the project being canceled in 2021 after years of criticism about the project’s environmental impact.

“Keystone XL Pipeline, long ago killed by Sleepy Joe Biden, may be awoken from the grave!” Trump added in the post.  

Due to exemptions on key goods, the tariffs were expected to hit only a fraction of U.S. imports from Canada.

Still, the list of affected goods features an array of food items such as dairy products, honey, whey protein and molasses; as well as alcoholic beverages like whiskey and vodka.

It all comes weeks after Trump imposed sweeping new tariffs on 60 trade partners, including the European Union. Those levies ramped up an effort to reconstruct far-reaching duties struck down by the Supreme Court earlier this year.

Unlike previous tariffs, the new Canada tariffs would have applied to products compliant with the United States-Mexico-Canada Agreement, or USMCA, a free trade agreement. The levies included significant exemptions, however, leaving out some top Canadian imports such as oil, gas and potash.

Trump first announced the tariffs in a series of executive orders last month, saying the move had been made in retaliation for Canadian policies he considers discriminatory against U.S. exports.

“President Trump is offsetting the burden and disadvantage on U.S. commerce from Canada’s discriminatory treatment of U.S. commerce and is leveling the playing field for crucial American exports–cars, alcohol, and dairy,” the White House said at the time.

In a statement last month, Canadian Prime Minister Mark Carney criticized a flurry of U.S. tariffs put forward since last year, saying Canada has “merely matched those measures.”

“This trade dispute has raised costs for families, particularly in the U.S. Canada stands ready to engage intensively to address outstanding issues with the U.S. to the mutual benefit of our citizens,” Carney said.

Trump has carried out on-again, off-again trade negotiations with Canada since he took office, aiming to resolve a dispute that began with tariffs announced by Trump early in his second term.

Trump sought to impose the tariffs under a legal authority enshrined in section 338 of the Tariff Act of 1930, which allows the president to enact levies up to 50% for countries found to have discriminated against the U.S. relative to their treatment of other nations.

The provision has never been invoked before, meaning the move lacks judicial precedent, Abigail Watt, an economist at UBS, said in a memo shared with ABC News.

Copyright © 2026, ABC Audio. All rights reserved.

Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed.The combination treatment regimen pairs the personalized vaccine with Merck's Keytruda, which had previously been used to treat the cancer alone.The treatment showed a 49% reduction of melanoma return after patients underwent surgery and a 59% reduction of metastasization of the cancer to distant organs.Key questions surrounding regulatory review of the vaccine remain.The Food and Drug Administration has not yet approved the vaccine. The agency will review the full data once it has been collected and submitted.While the FDA has already approved other cancer vaccines, this new treatment represents a step forward in the field as it uses mRNA technology and personalized treatment for each patient.Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators on filing submissions for approval of the regimen, the companies said in a joint press release.Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that he expects the treatment to be approved based on very positive trial results and made available to patients likely by early 2027.The vaccine uses genetic information from patients' individual tumors to identify and attack the cancer."It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself," Tarhini said.Melanoma is the deadliest form of skin cancer, with about 112,000 new cases expected in 2026, according to the American Cancer Society.The treatment is considered relatively safe, according to the companies. The most common side effects include fatigue, sore arm and chills.Treatments utilizing mRNA technologies are being used in trials for other forms of cancer, including that of the bladder, kidney, lungs, stomach and pancreas, according to Tarhini."I think it will certainly improve the outcome of our patients," Tarhini said. "We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."Copyright © 2026, ABC Audio. All rights reserved.
Read Next Story